<DOC>
	<DOCNO>NCT01147666</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety FG-4592 maintaining and/or correct hemoglobin ( Hb ) give subject End Stage Renal Disease ( ESRD ) maintenance hemodialysis</brief_summary>
	<brief_title>Study FG-4592 Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis</brief_title>
	<detailed_description>Dose range study consecutive cohort two subject population : patient normally respond current anemia treatment ( epoetin alfa ) ( `` normoresponders '' ) patient respond well current treatment ( `` hyporesponders '' ) . Normoresponders randomize study drug FG-4592 epoetin alfa ; hyporesponders randomize study drug FG-4592 epoetin alfa placebo . The study objective demonstrate FG-4592 effective maintaining hemoglobin ( Hb ) level convert epoetin alfa establish optimum start dos dose adjustment regimen Hb maintenance .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Key 1 . Age 18 75 year 2 . Endstage renal disease ( ESRD ) receive maintenance hemodialysis 3 . Two recent hemoglobin value obtain screen period must within range set : Croup A. Normoresponder Criteria : Hb range 8 week prior randomization within 9.0 13.5 g/dL Group B. Hyporesponder Criteria : Hb range 8 week prior randomization within 8.5 13.5 g/dL 4 . Epoetin alfa , dose requirement : Group A. Normoresponder Criteria Cohorts A1 A12 : Stable IV epoetin alfa dose baseline ( i.e. , 30 % fluctuation weekly dose ) 4 week prior study Day 3 Cohorts A1 A4 : Current previous ( past 4 week ) epoetin alfa dose range 25 85 IU/kg/dose , three time week ( TIW ) ; weekly dose 75 255 IU/kg/week Cohort A5 : Current previous ( past 4 week ) epoetin alfa dose range =/ &gt; 85 115 IU/kg/dose , TIW ; total weekly dose 255 335 IU/kg/week Cohort A9 : Current previous ( past 4 week ) epoetin alfa dose range =/ &gt; 85 150 IU/kg/dose , TIW ; total weekly dose 255 450 IU/kg/week Cohorts A6 A8 : Current previous ( past 4 week ) epoetin alfa dose range 25 115 IU/kg/dose , TIW , two time week ( BIW ) ; total weekly dose 75 345 IU/kg/week Cohorts A10 A12 : Optional cohort TBD , dose frequency dose range determine sponsor Group B. Hyporesponder Criteria : Cohort B1 ( complete ) : Current previous ( past 4 week ) epoetin alfa dose range 125 400 IU/kg/dose , TIW ; weekly dose 375 1200 IU/kg/week Cohort B2 B4 : Current previous ( past 4 week ) epoetin alfa dose range &gt; 115 IU/kg/dose , TIW ; total weekly dose &gt; 345 IU/kg/week requirement stability epoetin alfa dose 5 . Complete Blood Count ( CBC ) , Hematology , liver function blood test , serum folate vitamin B12 within acceptable limit 6 . Absence active chronic gastrointestinal bleed 7. hsCRP &lt; 60 mg/L normoresponders Cohorts A8 A12 enrol Amendment 3 ; hsCRP criterion hyporesponders 8 . Body weight : 40 140 kg ( dry weight ) 9 . Body mass index ( BMI ) : 18 45 kg/m2 10 . Dialysis vascular access via native arteriovenous fistula synthetic graft , permanent ( tunnel ) catheter ( via temporary catheter ) ; permanent temporary catheter , however , still prohibit Cohort A5 Key 1 . Anticipated change hemodialysis prescription 2 . Any clinically significant infection evidence underlie infection 3 . Positive following : Human immunodeficiency virus ( HIV ) ; hepatitis B surface antigen ( HBsAg ) ; antihepatitis C virus antibody ( antiHCV Ab ) 4 . History chronic liver disease 5 . New York Heart Association Class III IV congestive heart failure 6 . Chronic inflammatory disease could impact erythropoiesis ( e.g. , systemic lupus erythematosis , rheumatoid arthritis , celiac disease ) even currently remission 7 . History myelodysplastic syndrome 8 . History hemosiderosis , hemochromatosis , polycystic kidney disease , anephric 9 . Active hemolysis diagnosis hemolytic syndrome 10 . Known bone marrow fibrosis 11 . Uncontrolled symptomatic secondary hyperparathyroidism 12 . Any prior organ transplantation 13 . Drugtreated gastroparesis shortbowel syndrome 14 . History alcohol drug abuse ; positive drug screen substance prescribe subject 15 . Prior treatment FG4592 16 . Diagnosis suspicion renal cell carcinoma 17 . RBC transfusion within 12 week prior Day 1 , anticipate need RBC transfusion dose period 18 . IV iron supplement within 2 week prior Day 1 and/or unwilling withhold IV iron dosing/Treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Kidney</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>ESRD</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>CKD</keyword>
	<keyword>Renal</keyword>
	<keyword>Anemia</keyword>
	<keyword>Oral anemia treatment</keyword>
	<keyword>Hemoglobin level</keyword>
	<keyword>Blood count</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Normoresponder</keyword>
	<keyword>Hyporesponder</keyword>
</DOC>